Skip to main content
Supplement Research and Comparison WebsiteBest Price GuaranteeAbout Us
Supplement Research and Comparison Website

Lactobacillus brevis Strains from Fermented Aloe vera Survive Gastroduodenal Environment and Suppress Common Food Borne Enteropathogens

  • 2014-03-05
  • PLoS ONE 9(3)
    • Young‐Wook Kim
    • Young-ju Jeong
    • Ah-Young Kim
    • H. Son
    • Jong-Am Lee
    • Cheong-Hwan Jung
    • Chae-Hyun Kim
    • Jaeman Kim

Abstract

Five novel Lactobacillus brevis strains were isolated from naturally fermented Aloe vera leaf flesh. Each strain was identified by Random Amplified Polymorphic DNA (RAPD) analysis and 16S rRNA sequence comparison. These strains were highly tolerant to acid, surviving in pH2.5 for up to 4 hours, and resistant to 5% bile salts at 37°C for 18 hours. Due to its tolerance to acid and bile salts, one strain passed through the gastric barrier and colonised the intestine after oral administration. All five strains inhibited the growth of many harmful enteropathogens without restraining most of normal commensals in the gut and hence named POAL (Probiotics Originating from Aloe Leaf) strains. Additionally, each strain exhibited discriminative resistance to a wide range of antibiotics. The L. brevis POAL strains, moreover, expressed high levels of the glutamate decarboxylase (GAD) gene which produces a beneficial neurotransmitter, γ-aminobutyric acid (GABA). These characteristics in all suggest that the novel L. brevis strains should be considered as potential food additives and resources for pharmaceutical research.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Lactobacillus brevisColonization of the IntestineBeneficial
Moderate
Lactobacillus brevisIncreased GABA ProductionBeneficial
Large
Lactobacillus brevisReduced Pathogenic Bacteria LevelsBeneficial
Large
Lactobacillus brevis HA-112Colonization of the IntestineBeneficial
Moderate
Lactobacillus brevis HA-112Improved Survival in Gastroduodenal EnvironmentBeneficial
Large
Lactobacillus brevis HA-112Increased γ-Aminobutyric Acid (GABA) ProductionBeneficial
Moderate
Lactobacillus brevis HA-112Reduced Pathogenic Bacteria LevelsBeneficial
Large
Lactobacillus brevis LB01Efficient Intestinal ColonizationBeneficial
Large
Lactobacillus brevis LB01Improved Survival in Gastroduodenal EnvironmentBeneficial
Large
Lactobacillus brevis LB01Increased γ-Aminobutyric Acid (GABA) ProductionBeneficial
Moderate
Lactobacillus brevis LB01Reduced Enteropathogen ActivityBeneficial
Large
Lactobacillus brevis Lbr-35Improved Survival in Gastroduodenal EnvironmentBeneficial
Large
Lactobacillus brevis Lbr-35Increased γ-Aminobutyric Acid (GABA) ProductionBeneficial
Moderate
Lactobacillus brevis Lbr-35Reduced Enteropathogen GrowthBeneficial
Moderate
Lactobacillus brevis MAK11L82BColonization of the IntestineBeneficial
Moderate
Lactobacillus brevis MAK11L82BImproved Survival in Gastroduodenal EnvironmentBeneficial
Large
Lactobacillus brevis MAK11L82BIncreased γ-Aminobutyric Acid (GABA) ProductionBeneficial
Moderate
Lactobacillus brevis MAK11L82BReduced Pathogenic Bacteria LevelsBeneficial
Large
Lactobacillus brevis SBC8803Improved Survival in Gastroduodenal EnvironmentBeneficial
Large
Lactobacillus brevis SBC8803Increased γ-Aminobutyric Acid (GABA) ProductionBeneficial
Moderate
Lactobacillus brevis SBC8803Reduced Enteropathogenic BurdenBeneficial
Large
Lactobacillus brevis SD-5214Improved Survival in Gastroduodenal EnvironmentBeneficial
Large
Lactobacillus brevis SD-5214Increased Intestinal ColonizationBeneficial
Large
Lactobacillus brevis SD-5214Increased γ-Aminobutyric Acid (GABA) ProductionBeneficial
Moderate
Lactobacillus brevis SD-5214Reduced Pathogenic Bacteria LevelsBeneficial
Large
Lactobacillus brevis UALbr-02Altered Glutamate Decarboxylase Gene ExpressionBeneficial
Moderate
Lactobacillus brevis UALbr-02Improved Survival in Gastroduodenal EnvironmentBeneficial
Large
Lactobacillus brevis UALbr-02Increased Intestinal ColonizationBeneficial
Large
Lactobacillus brevis UALbr-02Reduced Enteropathogen ActivityBeneficial
Large
Lactobacillus brevis VPro 18Increased Production of Beneficial Neurotransmitter GABABeneficial
Moderate
⬆ Back to top
Unsubscribe anytime. See our Privacy Policy.
Pillser
Supplement Research and Comparison Website: evidence-based information about supplements, their benefits, potential risks, and their efficacy.
Join Our Community
Statements on this website have not been reviewed by the U.S. Food and Drug Administration. These products are not meant to diagnose, treat, cure, or prevent any disease. The information here is not a replacement for personal medical advice.